Development of a Reliable GADSAH Model for Differentiating AFP-negative Hepatic Benign and Malignant Occupying Lesions

References

• Marrero JA, Ahn J, Rajender Reddy K. ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol. 2014;109(9):1328–1347; quiz 1348. doi:10.1038/ajg.2014.213
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca a Cancer J Clinicians. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Liu J, Tang W, Budhu A, et al. A viral exposure signature defines early onset of hepatocellular carcinoma. Cell. 2020;182(2):317–328.e310. doi:10.1016/j.cell.2020.05.038
   PubMed Web of Science ®Google Scholar
• Takayama T, Makuuchi M, Kojiro M, et al. Early hepatocellular carcinoma: pathology, imaging, and therapy. Ann Surg Oncol. 2008;15(4):972–978. doi:10.1245/s10434-007-9685-0
   PubMed Web of Science ®Google Scholar
• Luo L, Wang T, Cheng M, et al. Rare benign liver tumors that require differentiation from hepatocellular carcinoma: focus on diagnosis and treatment. J Cancer Res Clin Oncol. 2023;149(7):2843–2854. doi:10.1007/s00432-022-04169-w
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Zhang G, Ha SA, Kim HK, et al. Combined analysis of AFP and HCCR-1 as an useful serological marker for small hepatocellular carcinoma: a prospective cohort study. Dis. Markers. 2012;32(4):265–271. doi:10.3233/dma-2011-0878
   PubMed Web of Science ®Google Scholar
• Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol. 2006;101(3):524–532. doi:10.1111/j.1572-0241.2006.00443.x
   PubMed Web of Science ®Google Scholar
• Chi X, Jiang L, Yuan Y, et al. A comparison of clinical pathologic characteristics between alpha-fetoprotein negative and positive hepatocellular carcinoma patients from Eastern and Southern China. BMC Gastroenterol. 2022;22(1):202. doi:10.1186/s12876-022-02279-w
   PubMed Web of Science ®Google Scholar
• Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706–1718.e1701. doi:10.1053/j.gastro.2018.01.064
   PubMed Web of Science ®Google Scholar
• Benhammou JN, Rich NE, Cholankeril G, et al. DETECT: Development of Technologies for Early HCC Detection. Gastroenterology. 2022;163(1):21–27 doi:10.1053/j.gastro.2022.03.024
   PubMed Web of Science ®Google Scholar
• Ariff B, Lloyd CR, Khan S, et al. Imaging of liver cancer. World J Gastroenterol. 2009;15(11):1289–1300. doi:10.3748/wjg.15.1289
   PubMed Web of Science ®Google Scholar
• Baranes L, Chiaradia M, Pigneur F, et al. Imaging benign hepatocellular tumors: atypical forms and diagnostic traps. Diagn. Interventional Imaging. 2013;94(7–8):677–695. doi:10.1016/j.diii.2013.05.002
   PubMedGoogle Scholar
• Cao X, Cao Z, Ou C, et al. Combination of serum paraoxonase/arylesterase 1 and antithrombin-III is a promising non-invasion biomarker for discrimination of AFP-negative HCC versus liver cirrhosis patients. Clin Res Hepatol Gastroenterol. 2021;45(5):101583. doi:10.1016/j.clinre.2020.11.013
   PubMed Web of Science ®Google Scholar
• Shu H, Zhang L, Chen Y, et al. Quantification of Intact O-Glycopeptides on haptoglobin in sera of patients with hepatocellular carcinoma and liver cirrhosis. Front Chem. 2021;9:705341. doi:10.3389/fchem.2021.705341
   PubMed Web of Science ®Google Scholar
• Kim DY, Toan BN, Tan CK, et al. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region. Clin mol hepatol. 2023;29(2):277–292. doi:10.3350/cmh.2022.0212
   PubMed Web of Science ®Google Scholar
• Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol. 2020;73(6):1368–1378. doi:10.1016/j.jhep.2020.07.025
   PubMed Web of Science ®Google Scholar
• Yang T, Xing H, Wang G, et al. A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis B. Clin. Chem. 2019;65(12):1543–1553. doi:10.1373/clinchem.2019.308965
   PubMed Web of Science ®Google Scholar
• Luo QQ, Li QN, Cai D, et al. The Index sAGP is valuable for distinguishing atypical hepatocellular carcinoma from atypical benign focal hepatic lesions. J Hepatocell Carcinoma. 2024;11:317–325. doi:10.2147/jhc.S443273
   PubMed Web of Science ®Google Scholar
• Handelman GS, Kok HK, Chandra RV, Razavi AH, Lee MJ, Asadi H. eDoctor: machine learning and the future of medicine. J Intern Med. 2018;284(6):603–619. doi:10.1111/joim.12822
   PubMed Web of Science ®Google Scholar
• Liu ZJ, Xu Y, Wang WX, et al. Development and application of hepatocellular carcinoma risk prediction model based on clinical characteristics and liver related indexes. World j Gastroint Oncol. 2023;15(8):1486–1496. doi:10.4251/wjgo.v15.i8.1486
   PubMed Web of Science ®Google Scholar
• An S, Zhan X, Liu M, Li L, Wu J. Diagnostic and prognostic nomograms for hepatocellular carcinoma based on PIVKA-II and serum biomarkers. Diagnostics. 2023;13(8). doi:10.3390/diagnostics13081442
   Web of Science ®Google Scholar
• Bureau of Medical Administration. 原发性肝癌诊疗指南(2022年版) [Standardization for diagnosis and treatment of hepatocellular carcinoma (2022 edition)]. Zhonghua Gan Zang Bing Za Zhi. 2022;30(4):367–388. Chinese. doi:10.3760/cma.j.cn501113-20220413-00193
   PubMedGoogle Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of benign liver tumours. J Hepatol. 2016;65(2):386–398. doi:10.1016/j.jhep.2016.04.001
   PubMed Web of Science ®Google Scholar
• Austin PC, White IR, Lee DS, van Buuren S. Missing data in clinical research: a tutorial on multiple imputation. Can J Cardiol. 2021;37(9):1322–1331. doi:10.1016/j.cjca.2020.11.010
   PubMed Web of Science ®Google Scholar
• Liu Y, Han Y, Chen B, et al. A new online dynamic nomogram: construction and validation of an assistant decision-making model for laryngeal squamous cell carcinoma. Front Oncol. 2022;12:829761. doi:10.3389/fonc.2022.829761
   PubMed Web of Science ®Google Scholar
• Li M, Wang Q, Lu P, et al. Development of a machine learning-based prediction model for chemotherapy-induced myelosuppression in children with wilms’ tumor. Cancers. 2023;15(4). doi:10.3390/cancers15041078
   Web of Science ®Google Scholar
• Ryerson AB, Eheman CR, Altekruse SF, et al. Annual Report to the Nation on the Status of Cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122(9):1312–1337. doi:10.1002/cncr.29936
   PubMed Web of Science ®Google Scholar
• Nguyen BN, Fléjou JF, Terris B, Belghiti J, Degott C. Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol. 1999;23(12):1441–1454. doi:10.1097/00000478-199912000-00001
   PubMed Web of Science ®Google Scholar
• McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011;15(2):223–243, vii–x. doi:10.1016/j.cld.2011.03.006
   Web of Science ®Google Scholar
• Walters GO, Miller FM, Worwood M. Serum ferritin concentration and iron stores in normal subjects. J Clin Pathol. 1973;26(10):770–772. doi:10.1136/jcp.26.10.770
   PubMed Web of Science ®Google Scholar
• Tran KT, Coleman HG, McCain RS, Cardwell CR. Serum biomarkers of iron status and risk of primary liver cancer: a systematic review and meta-analysis. Nutr Cancer. 2019;71(8):1365–1373. doi:10.1080/01635581.2019.1609053
   PubMed Web of Science ®Google Scholar
• Tang DJ, Lang YM, Feng YZ. Evaluation of combined assays of serum ferritin, alpha-1-antitrypsin and alpha-fetoprotein in liver cancer. Chinese Med J. 1992;105(11):900–904.
   PubMed Web of Science ®Google Scholar
• Nakano S, Kumada T, Sugiyama K, Watahiki H, Takeda I. Clinical significance of serum ferritin determination for hepatocellular carcinoma. Am J Gastroenterol. 1984;79(8):623–627.
   PubMed Web of Science ®Google Scholar
• Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39(12):2214–2229. doi:10.1111/liv.14223
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Sterling RK, Chung RT, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005;43(3):434–441. doi:10.1016/j.jhep.2005.03.019
   PubMed Web of Science ®Google Scholar
• Fouad R, Elsharkawy A, Abdel Alem S, et al. Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals. Eur J Gastroenterol Hepatol. 2019;31(9):1129–1134. doi:10.1097/meg.0000000000001400
   PubMed Web of Science ®Google Scholar
• Zhang K, Song P, Gao J, Li G, Zhao X, Zhang S. Perspectives on a combined test of multi serum biomarkers in China: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Drug Discoveries Ther. 2014;8(3):102–109. doi:10.5582/ddt.2014.01026
   PubMedGoogle Scholar
• Chen H, Zhang Y, Li S, et al. Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma. Cancer Manage Res. 2018;10:1947–1958. doi:10.2147/cmar.S167036
   PubMed Web of Science ®Google Scholar
• de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015;62(4):1190–1200. doi:10.1002/hep.27969
   PubMed Web of Science ®Google Scholar
• Jeng WJ, Papatheodoridis GV, Lok ASF. Hepatitis B. Lancet. 2023;401(10381):1039–1052. doi:10.1016/s0140-6736(22)01468-4
   PubMed Web of Science ®Google Scholar
• Vo T T, Poovorawan K, Charoen P, et al. Association between hepatitis B surface antigen levels and the risk of hepatocellular carcinoma in patients with chronic hepatitis B infection: systematic review and meta-analysis. Asian Pac J Cancer Prev. 2019;20(8):2239–2246. doi:10.31557/apjcp.2019.20.8.2239
   PubMedGoogle Scholar
• Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142(5):1140–1149.e1143; quiz e1113–1144. doi:10.1053/j.gastro.2012.02.007
   Web of Science ®Google Scholar
• Xi IL, Wu J, Guan J, et al. Deep learning for differentiation of benign and malignant solid liver lesions on ultrasonography. Abdom Radiol. 2021;46(2):534–543. doi:10.1007/s00261-020-02564-w
   PubMed Web of Science ®Google Scholar
• Yasaka K, Akai H, Abe O, Kiryu S. Deep learning with convolutional neural network for differentiation of liver masses at dynamic contrast-enhanced CT: a preliminary study. Radiology. 2018;286(3):887–896. doi:10.1148/radiol.2017170706
   PubMed Web of Science ®Google Scholar
• Shen H, Lv G, Lin H, et al. Development of an ultrasound prediction model to discriminate between malignant and benign liver lesions. Ultrasound Med Biol. 2020;46(4):952–958. doi:10.1016/j.ultrasmedbio.2019.12.018
   PubMed Web of Science ®Google Scholar